Expert Interview
Discussing Bristol Myers' COMMANDS (Reblozyl) & Geron's iMERGE (imetelstat) data from ASCO 2023 in MDS
Ticker(s): BMY, GERNInstitution: Johns Hopkins University School of Medicine
- Hematologist and Associate Professor of Oncology and Medicine at Johns Hopkins University School of Medicine.
- Currently manages 150 patients with LR-MDS and is familiar with results presented at the ASCO conference.
- Clinical Research Focus: Bone Marrow Failure Disorders; Bone Marrow Transplantation in Patients with Severe Aplastic Anemia; Novel Therapeutics for Myelodysplastic Syndromes and has been the principle investigator for over 40 single center and multicenter clinical trials in MDS and AA.
Roughly how many patients with MDS do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Reblozyl and Imetelstat based on the recent ASCO data?
Added By: c_adminDoes COMMANDS study support the broad (RS status agnostic label) in the first line for Reblozyl?
Added By: jelenanCould you please comment on differences in observed activity in RS negative patients between Reblozyl and KER-050 (Keros' molecule)? We are supposed to see an updated data for KER-050, Best in Class Reblozyl at EHA
Added By: jelenanAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
